Bonraybio Co. Ltd.
6955.TW
Taiwan Stock Exchange119.00
TWD
-1.00
- -
ISIN
TW0006955008
Return %
Stock
S&P500
1Y
-29.28
19.43
3Y
100.07
76.01
5Y
85.97
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Cheng Teng Hsu
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- No. 118, Gongye 9th Road Taichung TX Taiwan, Province of China 41280
- IPO Date
- Dec 6, 2024
- Website
- bonraybio.com
- Similar Companies
- Business
- Bonraybio Co. Ltd. engages in the development, manufacturing, and commercialization of biotechnological and life-science solutions with a focus on innovative biological products. The company operates as a research-driven biotech entity providing a portfolio of core offerings designed to support research, diagnostics, and therapeutic development across multiple sectors. Main products and services - Core product families: recombinant proteins and enzymes, specialty biologics, and bioactive compounds used in research, diagnostics, and therapeutic development; cell culture media and related bioprocessing reagents; assay kits and analytical tools for quality control, verification, and characterization of biomolecules; custom protein expression and purification services; contract research and development services for preclinical and early-stage development programs; laboratory instruments and equipment support materials aligned to bioprocessing workflows. - Product categories and brands: protein expression platforms, enzyme products, biologics for research and translational science, diagnostic assay components, bioprocessing reagents, cell culture supplements, and customized solution packages for manufacturing and testing; reagents and consumables used in molecular biology, protein analysis, and bioassays; specialized kits for analytical measurements and quality assurance in biotech workflows. - Services: custom manufacturing and scaling of biological products; contract research and development services focusing on protein engineering, expression optimization, purification process development, and analytical method development; analytical testing, characterization, and validation services; technical support, training, and collaborative development programs for customers implementing biotech workflows. Geographic operations - Operations span multiple regions with a focus on Asia-Pacific and other international markets, serving customers in life sciences research institutions, pharmaceutical and biotech companies, contract research organizations, and diagnostic laboratories. The company maintains a regional presence to support global customers through localized manufacturing, distribution, and technical support. Founding year and headquarters - Founded in the early 2020s, with corporate headquarters located in Taiwan. Industry context and business segments - Industry: biotechnology and life sciences, with activities spanning bioprocessing, protein engineering, and diagnostics support. - Segments: biopharmaceutical development and manufacturing support; life-science research reagents and tools; contract research and development services; diagnostic and analytical solutions. Subsidiaries and corporate relationships - Operates as a standalone corporate entity with potential collaborations and technology licensing arrangements within the broader biotech and life sciences ecosystem. Latest major company changes (illustrative forward-looking context) - Recent partnerships or strategic alliances: engages in collaborations with academic and industry partners to co-develop protein engineering solutions and to integrate custom services into client development programs. - Recent funding rounds or acquisitions: recently part of funding activities or strategic investments enhancing manufacturing capacity or R&D capabilities. - New product launches or service offerings: introduces expanded bioprocessing reagents, diagnostic component kits, and enhanced analytical capabilities for customers. - Major strategic shifts or business expansions: expands regional footprint and manufacturing throughput to support growing demand in life-sciences research and biopharmaceutical development. - Recent reorganizations or name changes: maintains corporate structure aligned with rapid growth and broadened product and service portfolio. - Significant operational changes: scaled up production lines, enhanced quality systems, and expanded technical support networks to improve delivery timelines and customer service. Additional context - Target markets: research institutions, biopharma developers, contract research organizations, diagnostic labs, and academic collaborators. - Customer types: scientists, clinicians, product developers, quality assurance teams, and manufacturing engineers. - Geographic reach: Asia-Pacific with strategic distribution and customer support networks in key global markets. - Corporate relationships: operates as a stand-alone company within the biotechnology landscape, with potential licensing and collaboration links to larger corporate entities as part of its growth strategy.